The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan.
 
Lowell L. Hart
Honoraria - Boehringer Ingelheim; Lilly; Novartis
Consulting or Advisory Role - Amgen; G1 Therapeutics; Genentech/Roche; Merck
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Lilly; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Novartis (Inst)
 
Zoran Gojko Andric
No Relationships to Disclose
 
Maen A. Hussein
Stock and Other Ownership Interests - Celgene (I)
Consulting or Advisory Role - Guardant Health
Speakers' Bureau - AMAG Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; HERON; Incyte; Pfizer
 
Renata Ferrarotto
Consulting or Advisory Role - Ayala Pharmaceuticals; Cellestia Biotech; E.R. Squibb Sons, LLC; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst)
 
J. Thaddeus Beck
No Relationships to Disclose
 
Janakiraman Subramanian
Consulting or Advisory Role - AstraZeneca; Biocept; Boehringer Ingelheim; Pfizer
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Lilly
Research Funding - Biocept; Paradigm
 
Davorin Z. Radosavljevic
No Relationships to Disclose
 
Dragana Jovanovic
No Relationships to Disclose
 
Krishna Kishore Pachipala
No Relationships to Disclose
 
Miroslav Samarzija
No Relationships to Disclose
 
Bojan Zaric
No Relationships to Disclose
 
Wahid Tewfik Hanna
No Relationships to Disclose
 
Raid Aljumaily
Consulting or Advisory Role - AstraZeneca; Regeneron
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst)
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; Lilly; Lilly; MedImmune; Novartis; PharmaMar; Sandoz; Seagen; Takeda
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst)
Other Relationship - Roche/Genentech
 
Rajesh K. Malik
Employment - G1 Therapeutics
Leadership - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Shannon R. Morris
Employment - G1 Therapeutics (I)
Leadership - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Misha L. Johnson
Employment - G1 Therapeutics; Innocrin Pharma
Stock and Other Ownership Interests - G1 Therapeutics
 
Zhao Yang
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
Steven Adler
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics
 
David R. Spigel
Leadership - TriStar Centennial Medical Center
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Evelo Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Oncology (Inst); Takeda (Inst); TRM Oncology (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Pfizer (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Genzyme; Intuitive Surgical; Lilly; Merck; Pfizer; Purdue Pharma; Spectrum Pharmaceuticals; Sysmex